This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Abstract Background: Clinically, 90%-95% of cases of CML have the characteristic t(9;22) (q34.1;q11.2) translocation that leads to the Philadelphia (Ph) chromosome. Rarely, patients with CML can present directly in a blast crisis (BC). While most blast crises are of myeloid origin, myeloid BC with ALL-like morphologic features and Ph-positive acute myeloid leukemia (AML) is rare, especially at the time of CML diagnosis. Case presentation: A 20-year-old man presented with Ph chromosome-positive AML mimicking acute lymphocytic leukemia (ALL). Bone marrow (BM) aspiration revealed AML with ALL-like morphologic features. The results of the immunophenotypic analysis suggested AML. Cytogenetic analysis of the BM cells revealed a 46,XY,t(3;14) (q21;q32),t(9;22)(q34;q11.2)[20] karyotype. Thus, we called the condition AML mimicking ALL. The patient was diagnosed with myeloid BC based on the combination of clinical, cytologic, and cytogenetic studies.
| BACKG ROU N D
Tumor biology and molecular genetic techniques have broadened our knowledge of genetic variation in cancers 1,2 such as CML-for example, Ph translocation t(9;22)(q34;q11), which is considered to be a diagnostic and prognostic biomarker in CML.
Clinically, 90%-95% of cases of CML have the characteristic t(9;22) (q34.1; q11.2) translocation that leads to the Ph chromosome. In addition, 20% and 2% of adult patients with ALL and AML have the exactly same cytogenetic marker, respectively. 3 AML is a heterogeneous disorder resulted from clonal multiplication of malignant myeloid precursors which were blocked differentiation in these cells, and it is the most common AL in adults, which is heterogeneous in the aspects of morphological, clinical, and cytogenetic features. Certain cytogenetic aberrations can be conducive to estimate AML subtypes and judge their reaction to treatment. 4 Roughly, 10%-12% of CML patients show additional chromosomal aberrations (ACAs) in chronic phase and blast crisis. ACAs, especially when complex, present to be a biomarker of CML evolution, and ACAs can be a important clue in treatment strategies. 5 Rarely, patients with CML can present directly in a blast crisis. While most blast crises are of myeloid origin, myeloid blast crisis with ALL-like morphologic features and Ph-positive AML is rare, especially at the time of CML diagnosis. 6, 7 This is the first case of CML blast crisis presented with AML of t(9;22) and t(3;14) double translocation mimicking ALL.
Clinical features were more suggestive of CML in myeloid blast crisis than de novo AML with the t(9;22). Further careful observation is required for clinical, cytologic, and cytogenetic changes during disease development. We started treatment with cytarabine, homoharringtonine, and imatinib mesylate after the diagnosis was established. The splenomegaly obviously shrank, peripheral blood smears showed blasts decreased to 10%, and eosinophilia and basophilia were easy to be seen after 26 days of combination chemotherapy. ( Figure 1D ) Unfortunately, we had to stop imatinib mesylate due to agranulocytosis and infection. After anti-infection treatment, although white blood cells gradually increased, the spleen enlarged simultaneously. Unfortunately, the patient refused combination chemotherapy again and was discharged on request due to his family's financial status. He was administered orally imatinib (400 mg/d) at home. However, the patient came back again due to uncontrollable fever one month after discharge, peripheral blood smears of the patient indicated 90% blast cells, and the disease gradually became difficult to control. [20] karyotype in all twenty examined cells our study presented with AML of t(9;22) and t (3;14) . These findings confirmed that these myeloid primitive cells originated from chronic myeloid leukemia clone. We presumed that our patients suffered from undetected chronic phase CML.
| C A S E PRE S ENTATI ON

| D ISCUSS I ON
| CON CLUS ION
In conclusion, this is the first case of CML BC presented with AML of t(9;22) and t(3;14) mimicking ALL. The case shows it is vital to combine clinical, cytologic, and cytogenetic analysis in distinguishing CML BC from de novo AML with the t(9;22).
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